# SUPPLEMENTARY PROSPECTUS

Monvia Limited
ACN 685 591 280

## 1. Introduction

This supplementary prospectus (**Supplementary Prospectus**) is issued by Monvia Limited ACN 685 591 280 (**Monvia** or the **Company**) and is dated 8 July 2026. It was lodged with the Australian Securities & Investments Commission (**ASIC**) on that date.

This Supplementary Prospectus supplements, and is intended to be read with, the replacement prospectus issued by the Company for its initial public offer dated 24 June 2026 (the **Prospectus**).

The information set out in this Supplementary Prospectus is taken to be included in the Prospectus. The contents of the Prospectus remain unchanged, other than as set out in this Supplementary Prospectus.

The matters stated in this Supplementary Prospectus are not considered to be materially adverse from the point of view of any investor.

Except where defined in this Supplementary Prospectus or inconsistent with the context, terms defined in the Prospectus have the same meanings when used in this Supplementary Prospectus.

Neither ASIC nor ASX Limited ACN 008 624 691 (including the financial market operated by it known as the Australian Securities Exchange) (**ASX**) takes responsibility for the contents of this Supplementary Prospectus or the investment to which it relates.

## 2. Purpose of Supplementary Prospectus

The purpose of this Supplementary Prospectus is to:

(a) extend the Closing Date of the Offer under the Prospectus to 8 July 2026; and

(b) provide additional information required by ASX in relation to the Company's use of funds and expenditure commitments.

## 3. Prospectus amendments

### 3.1 Introduction

The Prospectus is amended on the basis set out in this section 3.

### 3.2 Extension of Closing Date of Offer

The Closing Date of the Offer under the Prospectus is extended to 5:00pm WST Wednesday, 8 July 2026.

All references to the Closing Date of "29 June 2026" in the Prospectus are amended to "8 July 2026".

The Indicative Timetable in the "Key Offer Information" Section of the Prospectus is amended as follows:

## Indicative Timetable

| Event | Target Date |
|---|---|
| Lodgement of Prospectus | 24 June 2026 |
| Expiry of Exposure Period | 24 June 2026 |
| Opening Date of the Offer | 25 June 2026 |
| Closing Date of the Offer (5:00pm WST) | 8 July 2026 |
| Issue of Shares under the Offer | 16 July 2026 |
| Despatch of Holding Statements | 17 July 2026 |
| Shares commence trading on ASX | 24 July 2026 |

**Note:** These dates are indicative only and subject to change. The Company, acting in consultation with the Joint Lead Managers, may decide to vary these dates without notice.

## 3.3 Use of funds and expenditure commitments

Section 5.3 of the Prospectus (use of funds) is replaced with the following:

### 5.3 Use of funds and expenditure commitments

The Company intends to use its current funds of approximately $1,896,000 cash on hand as at the Original Prospectus Date, and the funds raised from the Offer as set out in the table below. The table below states the Company's commitments and expenditure program for the Company's cash funds following completion of the Offer and admission of the Company to the Official List (**Admission**):

| Use | Amount [1] | Percentage of available funds | Expenditure program |
|---|---|---|---|
| **Funds available** | | | |
| **Cash on hand as at the Original Prospectus Date** | $1,896,000 | | |
| **Funds from the Offer** | $17,500,000 | | |
| **Total funds available** | $19,396,000 | | |
| **Use of funds and expenditure commitments** | | | |
| **Redemption of Series B Preference Shares[2]** | $12,500,000 | 64.45% | At the time of Admission |
| **Investment in sales and marketing and international expansion** | $1,700,000 | 8.77% | Within 12 months of Admission |
| **Costs of the Offer[3]** | $1,385,665 | 7.14% | At the time of Admission |
| **General working capital[4, 5]** | $3,810,335 | 19.64% | Within 12 months of Admission |
| **Total** | **$19,396,000** | **100%** | |

**Notes:**

1. The stated use of funds is current as at the Prospectus Date and as at the date of the Supplementary Prospectus. The use of funds may change depending on any intervening events or changes in the Company's circumstances. The Board reserves the right to change the way funds are used and applied.
2. Relevant material terms of the Series B Preference Shares are detailed in Section 10.3.
3. Costs of the Offer includes the Joint Lead Managers' fees and the other costs identified in Section 11.3. The Company has paid approximately $329,335 of the costs of the Offer at the Original Prospectus Date.
4. The Company's operations and expenses incurred in the ordinary course of business is primarily sourced from revenue generated from its customers (refer to Section 3.4). In addition to revenue generated from its operations, the Company intends to use the remaining funds from the Offer to fund the Company's general working capital expenses in the following proportions: 50% towards R&D; 22% towards staff costs and the remaining 28% towards administrative expenses, including regulatory, legal, compliance, and other operational costs, based on current spending patterns.
5. As noted in Section 3.9, the Company has in place a loan facility of $6,000,000 (as at the Prospectus Date and excluding interest). Whilst the Company will have sufficient cash to prepay the full amount of this loan facility upon completion of the Offer, the loan facility is not due and payable until 30 June 2027. Accordingly, the Company does not currently intend to use any Offer proceeds towards such prepayment but rather intends to repay this loan using cash generated from the Company's operations. The Directors believe that funds raised from revenues generated from ongoing operations of the Company will be sufficient to fund repayment of the loan facility on or before 30 June 2027.

Based on the intended use of funds and expenditure commitments as detailed above, the amounts raised pursuant to the Offer, combined with expected revenues generated from ongoing operations, will provide the Company with sufficient funding for its operations for the foreseeable future and for the period of 12 months from Admission.

The Directors have made enquiries and nothing has come to their attention to suggest that the Group is not continuing to earn profit from continuing operations up to the Prospectus Date. However, the Company may require further financing in the future. See Section 8.4(a) for further details about the risks associated with the Company's future capital requirements.

The Company's objectives it is seeking to achieve from its Admission and the Offer are stated in this Prospectus, particularly at Section 5.2.

The Directors believe that with funds raised from the Offer the Company will have enough working capital at the time of Admission for the Company to carry out its stated objectives as detailed in this Prospectus.

# 4. Directors' authorisation

This Supplementary Prospectus is issued by the Company pursuant to resolution of the Directors.

Each Director has given, and has not withdrawn their consent, to the lodgement of this Supplementary Prospectus with ASIC.

This Supplementary Prospectus has been signed for and on behalf of the Company by:

**Russell Baskerville**

Non-Executive Director and Chairman
Monvia Limited

8 July 2026